Oxycodone controlled release - Pain Therapeutics

Drug Profile

Oxycodone controlled release - Pain Therapeutics

Alternative Names: Extended-release oxycodone capsules CII; ORADUR®-oxycodone; Oxycodone CII; Oxycodone extended release; PF-00345439; PTI-821; Remoxy; REMOXY® ER

Latest Information Update: 08 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DURECT Corporation
  • Developer Pain Therapeutics
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Preregistration Pain

Most Recent Events

  • 06 Aug 2018 Pain Therapeutics receives complete response Letter from USFDA for oxycodone contolled release
  • 26 Jun 2018 Majority of members in FDA Advisory Committee Meeting votes against approval for oxycodone controlled release for Pain
  • 01 Mar 2018 US FDA accepts NDA for Oxycodone controlled release for pain for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top